| Today’s Big NewsSep 5, 2023 |
| By Annalee Armstrong The world’s pharmaceutical companies are set to invest $302 billion in R&D by 2028—but what will they get in return? Fierce Biotech explores the 10 therapies with the highest potential value. |
|
|
|
By Gabrielle Masson The latest financing will in part go toward VGA039, an early-stage mAB being developed by Star's offshoot Vega to treat von Willebrand disease. |
By Nick Paul Taylor Zenas BioPharma has flipped regional rights to its bifunctional monoclonal antibody obexelimab. Bristol Myers Squibb has taken the other side of the deal, paying $50 million upfront for certain Asian rights to an asset that Zenas picked up from Xencor in return for a stake in its business less than two years ago. |
By Max Bayer Tonix Pharmaceuticals says its fibromyalgia treatment turned long COVID med failed to improve severe pain in patients with the post-COVID condition. However, some potential improvements in measurements of fatigue and sleep quality are guiding the company toward a new focus. |
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Register today & Save $200!
|
|
By Nick Paul Taylor BioCardia’s dive into its paused phase 3 heart failure trial has failed to identify reasons to be optimistic about the primary endpoint. Weeks after the monitoring board recommended pumping the brakes, the biotech has revealed the study is unlikely to meet its main objective, putting another dent in its share price. |
By Kevin Dunleavy Add Novartis to the list of biopharma giants that have filed lawsuits against the U.S. government as a reaction to the Inflation Reduction Act. The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart-failure treatment Entresto was among 10 drugs subject to price negotiations in 2026. |
By Nick Paul Taylor Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics. |
By Paige Minemyer As more and more cell and gene therapies come to the market, these high-cost drugs are set to have a major impact on cash-strapped Medicaid programs, according to a new analysis from Prime Therapeutics. |
By Fraiser Kansteiner After jumping into the mRNA game back in 2018, CanSino has built a facility in Shanghai that can produce up to 200 million vaccine doses a year, the company’s co-founder and CEO Xuefeng Yu told Reuters in a recent interview. |
|
Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today.
|
|
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
